The first portable and intelligent heart monitor has been developed

The device, which should reach the market this year with the name Nexcor, was developed by a group of specialists in Brazil is the first smart portable heart monitor in the world, which allows remote sending electrocardiograms, ocation of the patient for assistance and early detection heart problems. 

This device automatically detects earliest variations of heart diseases, measures the frequency and makes an assessment of rhythm and alterations.

The monitor is a unit slightly larger than a mobile phone that the patient wears around the waist and is connected to four electrodes placed on the chest. The signals sent help prevent

arrhythmias, ischemia and myocardial infarction  and has a patient fall detector, an emergency button and a communicator that allows the patient to talk to an expert immediately if he/she feels unwell.

This semester the United States and Europe will receive the first models produced, which will be rented to patients with an estimated price of $ 300 per week.

SOLACI.ORG

More articles by this author

Women Present Lower Risk of Sport Related Sudden Death Compared to Men

According to this recent analysis published in Eur Heart J, women would have a far lower chances of dying suddenly for physical exertion during...

Saturated Fats: Dietary Angels or Demons?

In order to reduce cardiovascular events, dietary guidelines recommend restricting saturated fatty acids—without taking into account differences among them—to <10% of the daily caloric...

Low-Carb Diet and Coronary Artery Calcium Progression

People on low carb diets since a young age present increased risk of coronary artery calcium progression, particularly when carbs are replaced by animal...

Number of Hours of Sleep and Risk of Stroke

Sleep duration (either short or long) affect the risk of stroke according to this recent analysis. We had visited a study published in JACC...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...